MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Triple Helix _ Translation, Commercialization, Technology Transfer, SBIR/STTR, OTA, NonTraditional / New Business Models
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Research Triangle, North Carolina
*Bioscience Regional Clusters & HotSpots
*Industry: Northern California & Silicon Valley
SARcode
Parents
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
*Industry: Northern California & Silicon Valley
*Portfolio Companies: Alta
*Portfolio Companies: Clarus
Industry: Canada
Children
Brisbane, California
Dry eye syndrome is a prevalent and often chronic condition estimated to affect approximately 20 million people in the US.
Founded 2008
In December, 2006 SARcode secured $25 million in a financing co-led by Clarus Ventures and Alta Partners.
It is among the most common diseases treated by ophthalmologists throughout the world
SARcode Pulls in 44 Million Series B Financing (2011)
SARcode's proprietary compound has demonstrated the ability to alleviate both the signs and symptoms of dry eye by directly targeting the inflammatory origin of this debilitating disease
Series B $44M by OnBioVC
Small molecule LFA-1 inhibitors to treat inflammatory diseases.
The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.